View Item 

Show simple item record

Outcomes of immunosuppression minimization and withdrawal early after liver transplantation

dc.contributor.authorShaked, Abraham
dc.contributor.authorDesMarais, Michele R.
dc.contributor.authorKopetskie, Heather
dc.contributor.authorFeng, Sandy
dc.contributor.authorPunch, Jeffrey D.
dc.contributor.authorLevitsky, Josh
dc.contributor.authorReyes, Jorge
dc.contributor.authorKlintmalm, Goran B.
dc.contributor.authorDemetris, Anthony J.
dc.contributor.authorBurrell, Bryna E.
dc.contributor.authorPriore, Allison
dc.contributor.authorBridges, Nancy D.
dc.contributor.authorSayre, Peter H.
dc.date.accessioned2019-05-31T18:24:59Z
dc.date.available2020-07-01T17:47:46Zen
dc.date.issued2019-05
dc.identifier.citationShaked, Abraham; DesMarais, Michele R.; Kopetskie, Heather; Feng, Sandy; Punch, Jeffrey D.; Levitsky, Josh; Reyes, Jorge; Klintmalm, Goran B.; Demetris, Anthony J.; Burrell, Bryna E.; Priore, Allison; Bridges, Nancy D.; Sayre, Peter H. (2019). "Outcomes of immunosuppression minimization and withdrawal early after liver transplantation." American Journal of Transplantation 19(5): 1397-1409.
dc.identifier.issn1600-6135
dc.identifier.issn1600-6143
dc.identifier.urihttps://hdl.handle.net/2027.42/149209
dc.publisherWiley Periodicals, Inc.
dc.subject.otherimmunosuppression/immune modulation
dc.subject.otherclinical research/practice
dc.subject.otherclinical trial
dc.subject.otherimmunosuppressive regimens ‐ minimization/withdrawal
dc.subject.otherinfection and infectious agents ‐ viral: hepatitis C
dc.subject.otherliver transplantation/hepatology
dc.subject.othertolerance
dc.titleOutcomes of immunosuppression minimization and withdrawal early after liver transplantation
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149209/1/ajt15205.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149209/2/ajt15205_am.pdf
dc.identifier.doi10.1111/ajt.15205
dc.identifier.sourceAmerican Journal of Transplantation
dc.identifier.citedreferenceLerut J, Mathys J, Verbaandert C, et al. Tacrolimus monotherapy in liver transplantation: one‐year results of a prospective, randomized, double‐blind, placebo‐controlled study. Ann Surg. 2008; 248 ( 6 ): 956 ‐ 967.
dc.identifier.citedreferenceLondoño MC, Rimola A, O’Grady J, Sanchez‐Fueyo A. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol. 2013; 59 ( 4 ): 872 ‐ 879.
dc.identifier.citedreferenceBenítez C, Londoño MC, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013; 58 ( 5 ): 1824 ‐ 1835.
dc.identifier.citedreferenceFeng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. 2012; 307 ( 3 ): 283 ‐ 293.
dc.identifier.citedreferenceDe Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012; 12 ( 11 ): 3008 ‐ 3020.
dc.identifier.citedreferenceSaliba F, Duvoux C, Gugenheim J, et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial. Am J Transplant. 2017; 17 ( 7 ): 1843 ‐ 1852.
dc.identifier.citedreferenceFischer L, Saliba F, Kaiser GM, et al. Three‐year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow‐up results from a randomized, Multicenter Study. Transplantation. 2015; 99 ( 7 ): 1455 ‐ 1462.
dc.identifier.citedreferenceDemetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology. 2000; 31 ( 3 ): 792 ‐ 799.
dc.identifier.citedreferenceRodríguez‐Perálvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013; 59 ( 6 ): 1193 ‐ 1199.
dc.identifier.citedreferenceRodriguez‐Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta‐analysis. Am J Transplant. 2012; 12 ( 10 ): 2797 ‐ 2814.
dc.identifier.citedreferenceAhmed A, Gonzalez SA, Cholankeril G, et al. Treatment of patients waitlisted for liver transplant with all‐oral direct‐acting antivirals is a cost‐effective treatment strategy in the United States. Hepatology. 2017; 66 ( 1 ): 46 ‐ 56.
dc.identifier.citedreferenceAzab M, Shah S, Liu X, et al. Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations. J Hepatol. 2017; 68: 626 ‐ 627.
dc.identifier.citedreferenceLevey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139: 137 ‐ 147.
dc.identifier.citedreferenceBanff Working Group, Demetris AJ. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006; 44 ( 2 ): 489 ‐ 501.
dc.identifier.citedreferenceWatt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post‐liver transplant: results of the NIDDK long‐term follow‐up study. Am J Transplant. 2010; 10 ( 6 ): 1420 ‐ 1427.
dc.identifier.citedreferenceOjo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003; 349 ( 10 ): 931 ‐ 940.
dc.identifier.citedreferenceLerut JP, Pinheiro RS, Lai Q, et al. Is minimal, [almost] steroid‐free immunosuppression a safe approach in adult liver transplantation? Long‐term outcome of a prospective, double blind, placebo‐controlled, randomized, investigator‐driven study. Ann Surg. 2014; 260 ( 5 ): 886 ‐ 891; discussion 891‐2.
dc.identifier.citedreferenceVasudev B, Hariharan S, Hussain SA, et al. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int. 2005; 68 ( 4 ): 1834 ‐ 1839.
dc.identifier.citedreferenceTakatsuki M, Soyama A, Torashima Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation. 2001; 72 ( 3 ): 449 ‐ 454.
dc.identifier.citedreferenceMazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997; 63 ( 2 ): 243 ‐ 249.
dc.identifier.citedreferenceTryphonopoulos P, Ruiz P, Weppler D, et al. Long‐term follow‐up of 23 operational tolerant liver transplant recipients. Transplantation. 2010; 90 ( 12 ): 1556 ‐ 1561.
dc.identifier.citedreferencePerito ER, Mohammad S, Rosenthal P, et al. Posttransplant metabolic syndrome in the withdrawal of immunosuppression in Pediatric Liver Transplant Recipients (WISP‐R) pilot trial. Am J Transplant. 2015; 15 ( 3 ): 779 ‐ 785.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajt15205.pdf
Size:
719.8KB
Format:
PDF
View/Open
Name:
ajt15205_am.pdf
Size:
409.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.